AIM Hemispherx BioPharma Inc.

3.1
+1.44  (+87%)
Previous Close 1.66
Open 3.36
Price To Book 1.42
Market Cap 7,570,290
Shares 2,442,029
Volume 6,515,430
Short Ratio 0.84
Av. Daily Volume 98,795

NewsSee all news

  1. AIM ImmunoTech Inc. Announces the U.S. Department of Defense's Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer

    New Ampligen-Related Strategy for Treating Advanced Breast Cancer Earns 'Breakthrough Award'OCALA, FL / ACCESSWIRE / September 19, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused

  2. AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer

    OCALA, FL / ACCESSWIRE / September 16, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency

  3. AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City

    OCALA, FL / ACCESSWIRE / September 13, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency

  4. AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center

    OCALA, FL / ACCESSWIRE / September 10, 2019 / AIM ImmunoTech Inc., (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL February 4, 2013.
Ampligen
CFS
Phase 1 data due 2020.
Ampligen, Intron A, celecoxib and pembrolizumab
Triple-Negative Breast Cancer
Phase 2 data due 2020.
Ampligen, Intron A, and celecoxib
Colorectal cancer
Phase 2 initiation of patient dosing announced June 12, 2019 with data due 2021.
Ampligen, cisplatin and pembrolizumab
Ovarian cancer
Phase 2 trial to commence June 2019.
Ampligen, Intron A
Prostate Cancer

Latest News

  1. AIM ImmunoTech Inc. Announces the U.S. Department of Defense's Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer

    New Ampligen-Related Strategy for Treating Advanced Breast Cancer Earns 'Breakthrough Award'OCALA, FL / ACCESSWIRE / September 19, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused

  2. AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer

    OCALA, FL / ACCESSWIRE / September 16, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency

  3. AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City

    OCALA, FL / ACCESSWIRE / September 13, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency

  4. AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center

    OCALA, FL / ACCESSWIRE / September 10, 2019 / AIM ImmunoTech Inc., (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency